company background image
CRNX

Crinetics Pharmaceuticals NasdaqGS:CRNX Stock Report

Last Price

US$18.59

Market Cap

US$994.7m

7D

1.6%

1Y

-5.5%

Updated

27 Jun, 2022

Data

Company Financials +
CRNX fundamental analysis
Snowflake Score
Valuation1/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

CRNX Stock Overview

Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors.

Crinetics Pharmaceuticals Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Crinetics Pharmaceuticals
Historical stock prices
Current Share PriceUS$18.59
52 Week HighUS$28.95
52 Week LowUS$15.91
Beta1.42
1 Month Change10.72%
3 Month Change-5.49%
1 Year Change-5.54%
3 Year Change-25.67%
5 Year Changen/a
Change since IPO-24.15%

Recent News & Updates

Jun 15
We're Not Very Worried About Crinetics Pharmaceuticals' (NASDAQ:CRNX) Cash Burn Rate

We're Not Very Worried About Crinetics Pharmaceuticals' (NASDAQ:CRNX) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Jun 13

Crinetics: Late-Stage Acromegaly Disease Studies Will Be Major Inflection Point

Two ongoing studies for use of paltusotine for treatment of patients with Acromegaly are PATHFNDR-1 and PATHFNDR-2; Results from both studies expected 2023. Paltusotine is also being explored for the treatment of patients with neuroendocrine tumors in a phase 2 study. Phase 1 proof of concept was established with CRN04777 for treatment of patients with congenital hyperinsulinism; phase 2 study expected to start 2nd half of 2022. Crinetics has around $444.7 million in cash including the most recent offering done in April of 2022, it believes that all this cash should be enough to fund its operations into the 2nd half of 2024.

Shareholder Returns

CRNXUS BiotechsUS Market
7D1.6%10.3%6.3%
1Y-5.5%-24.5%-18.8%

Return vs Industry: CRNX exceeded the US Biotechs industry which returned -24.3% over the past year.

Return vs Market: CRNX exceeded the US Market which returned -18.4% over the past year.

Price Volatility

Is CRNX's price volatile compared to industry and market?
CRNX volatility
CRNX Average Weekly Movement13.4%
Biotechs Industry Average Movement13.2%
Market Average Movement8.1%
10% most volatile stocks in US Market16.7%
10% least volatile stocks in US Market3.2%

Stable Share Price: CRNX is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 13% a week.

Volatility Over Time: CRNX's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
2008143R. Struthershttps://www.crinetics.com

Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III clinical trial for the treatment of acromegaly, as well as completed phase II clinical trial to treat carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). The company is also developing CRN04777, an oral selective nonpeptide somatostatin type 5 receptor agonist, which is in phase I clinical trial for the treatment of congenital hyperinsulinism; and CRN04894, an oral adrenocorticotrophic hormone antagonist that is in phase I clinical trial for the treatment of Cushing's and congenital adrenal hyperplasia diseases.

Crinetics Pharmaceuticals Fundamentals Summary

How do Crinetics Pharmaceuticals's earnings and revenue compare to its market cap?
CRNX fundamental statistics
Market CapUS$994.67m
Earnings (TTM)-US$119.37m
Revenue (TTM)US$4.21m

236.3x

P/S Ratio

-8.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
CRNX income statement (TTM)
RevenueUS$4.21m
Cost of RevenueUS$94.92m
Gross Profit-US$90.71m
Other ExpensesUS$28.65m
Earnings-US$119.37m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-2.23
Gross Margin-2,155.24%
Net Profit Margin-2,835.99%
Debt/Equity Ratio0%

How did CRNX perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is CRNX undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • PEG Ratio

Key Valuation Metric

Which metric is best to use when looking at relative valuation for CRNX?

Other financial metrics that can be useful for relative valuation.

CRNX key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue161.3x
Enterprise Value/EBITDA-5.8x
PEG Ration/a

Price to Book Ratio vs Peers

How does CRNX's PB Ratio compare to its peers?

CRNX PB Ratio vs Peers
The above table shows the PB ratio for CRNX vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPBEstimated GrowthMarket Cap
Peer Average4.1x
FGEN FibroGen
6.9x24.8%US$1.1b
ARQT Arcutis Biotherapeutics
4.4x67.8%US$1.1b
KYMR Kymera Therapeutics
2.5x-6.9%US$1.1b
KDNY Chinook Therapeutics
2.7x10.9%US$1.2b
CRNX Crinetics Pharmaceuticals
3.3x-14.7%US$994.7m

Price-To-Book vs Peers: CRNX is good value based on its Price-To-Book Ratio (3.3x) compared to the peer average (4.1x).


Price to Earnings Ratio vs Industry

How does CRNX's PE Ratio compare vs other companies in the US Biotechs Industry?

Price-To-Book vs Industry: CRNX is expensive based on its Price-To-Book Ratio (3.3x) compared to the US Biotechs industry average (1.6x)


Price to Book Ratio vs Fair Ratio

What is CRNX's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

CRNX PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio3.3x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate CRNX's Price-To-Book Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of CRNX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate CRNX's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate CRNX's fair value for valuation analysis.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate CRNX's PEG Ratio to determine if it is good value.


Discover undervalued companies

Future Growth

How is Crinetics Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?

Future Growth Score

2/6

Future Growth Score 2/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


-14.7%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: CRNX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: CRNX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: CRNX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: CRNX's revenue (71.1% per year) is forecast to grow faster than the US market (8.4% per year).

High Growth Revenue: CRNX's revenue (71.1% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if CRNX's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Past Performance

How has Crinetics Pharmaceuticals performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-45.2%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: CRNX is currently unprofitable.

Growing Profit Margin: CRNX is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: CRNX is unprofitable, and losses have increased over the past 5 years at a rate of 45.2% per year.

Accelerating Growth: Unable to compare CRNX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CRNX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (96.9%).


Return on Equity

High ROE: CRNX has a negative Return on Equity (-39.39%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is Crinetics Pharmaceuticals's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: CRNX's short term assets ($328.2M) exceed its short term liabilities ($20.3M).

Long Term Liabilities: CRNX's short term assets ($328.2M) exceed its long term liabilities ($10.0M).


Debt to Equity History and Analysis

Debt Level: CRNX is debt free.

Reducing Debt: CRNX has no debt compared to 5 years ago when its debt to equity ratio was 1.3%.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: CRNX has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: CRNX has sufficient cash runway for 2.5 years if free cash flow continues to reduce at historical rates of 41.2% each year.


Discover healthy companies

Dividend

What is Crinetics Pharmaceuticals's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate CRNX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate CRNX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if CRNX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CRNX's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as CRNX has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

1.3yrs

Average management tenure


CEO

R. Struthers (59 yo)

13.5yrs

Tenure

US$4,144,049

Compensation

Dr. R. Scott Struthers, Ph.D. founded Crinetics Pharmaceuticals, Inc. in November 2008 and serves as its Chief Executive Officer and President since December 2008. He is Chairman at Radionetics Oncology, I...


CEO Compensation Analysis

Compensation vs Market: R.'s total compensation ($USD4.14M) is about average for companies of similar size in the US market ($USD4.02M).

Compensation vs Earnings: R.'s compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: CRNX's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.


Board Members

Experienced Board: CRNX's board of directors are not considered experienced ( 1.8 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 42.3%.


Top Shareholders

Company Information

Crinetics Pharmaceuticals, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Crinetics Pharmaceuticals, Inc.
  • Ticker: CRNX
  • Exchange: NasdaqGS
  • Founded: 2008
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$994.673m
  • Shares outstanding: 53.51m
  • Website: https://www.crinetics.com

Number of Employees


Location

  • Crinetics Pharmaceuticals, Inc.
  • Building No. 2
  • 10222 Barnes Canyon Road
  • San Diego
  • California
  • 92121
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/06/27 00:00
End of Day Share Price2022/06/27 00:00
Earnings2022/03/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.